Lupus

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stohl, W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stohl, W
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Lupus, Vol. 13, No. 5, 317-322 (2004)
DOI: 10.1191/0961203304lu1019oa

A therapeutic role for BLyS antagonists

W Stohl

Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, USA, stohl{at}usc.edu

B lymphocytestimulator (BLyS) is a vital B cell survivalfactor. Overexpressionof BLyS in mice may lead to systemic lupus erythematosus (SLE)-like disease, and treatment of bona fide SLE mice with BLyS antagonists ameliorates disease progression and enhances survival. BLyS overexpression is common in human SLE, and results from a phase I clinical trial with a BLyS antagonistin human SLE have shown the antagonist to be biologicallyactive and safe. These features collectivelypoint to BLyS as an attractive therapeutic target in human disease.

Key Words: APRIL • B cells • biologic antagonists • BLyS • SLE


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
M. Carbonatto, P. Yu, M. Bertolino, E. Vigna, S. Steidler, L. Fava, C. Daghero, B. Roattino, M. Onidi, M. Ardizzone, et al.
Nonclinical Safety, Pharmacokinetics, and Pharmacodynamics of Atacicept
Toxicol. Sci., September 1, 2008; 105(1): 200 - 210.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
E. MacDermott, A. Adams, and T. Lehman
Review: Systemic lupus erythematosus in children: current and emerging therapies
Lupus, August 1, 2007; 16(8): 677 - 683.
[Abstract] [PDF]

Home page
 Ann Rheum DisHome page
M P Cancro
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity
Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii34 - iii36.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
S Vasoo and G R. Hughes
Theory, targets and therapy in systemic lupus erythematosus
Lupus, March 1, 2005; 14(3): 181 - 188.
[Abstract] [PDF]

Home page
 LupusHome page
J T Merrill
BLyS antagonists and peptide tolerance induction
Lupus, March 1, 2005; 14(3): 204 - 209.
[Abstract] [PDF]

Home page
 LupusHome page
H Tahir and D A Isenberg
Novel therapies in lupus nephritis
Lupus, January 1, 2005; 14(1): 77 - 82.
[Abstract] [PDF]